Immunomedics Announces Presentations at Gastrointestinal Cancers Symposium Showcasing Advances in Pancreatic Cancer Diagnosis and Therapy

MORRIS PLAINS, N.J., Jan. 12, 2012 (GLOBE NEWSWIRE) -- Immunomedics, Inc. IMMU, a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that 4 studies focusing on early detection and treatment of pancreatic cancer have been accepted for presentation at the 2012 Gastrointestinal Cancers Symposium, scheduled for January 19 – 21, 2012, in San Francisco, CA. Co-sponsors of the Symposium include the American Gastroenterological Association (AGA) Institute, the American Society of Clinical Oncology, the American Society for Radiation Oncology and the Society of Surgical Oncology.

All 4 studies are based on clivatuzumab, the Company's proprietary humanized antibody that is highly specific as a biomarker of pancreatic ductal cancer. The schedule and meeting places for the presentations, together with the abstract and poster board numbers, are listed below:

• "Detection of early-stage pancreatic ductal adenocarcinoma (PDAC): Sensitivity, specificity, and discriminatory properties of the serum-based PAM4-immunoassay." [Abstract #: 151, General Session I: Cancers of the Pancreas, Small Bowel and Hepatobiliary Tract: Prevention, Screening, and Diagnosis.  Oral presentation on Friday, January 20, 8:15 am – 8:30 am, Level 3, Ballroom]
  [Abstract #: 151, General Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract. Poster Board #: A3. Friday, January 20, 11:45 am – 1:45 pm and 5:15 pm – 6:45 pm, Level 1, West Hall]
• "Combination of the PAM4 and CA19-9 biomarkers to improve the detection of pancreatic adenocarcinoma." [Abstract #: 164, General Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract.  Poster Board #: A16.  Friday, January 20, 11:45 am – 1:45 pm and 5:15 pm – 6:45 pm, Level 1, West Hall]
• "Use of monoclonal antibody PAM4 to differentiate pancreatic ductal adenocarcinoma (PDAC) from chronic pancreatitis and benign non-mucinous cysts of the pancreas." [Abstract #: 188, General Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract. Poster Board #: A40. Friday, January 20, 11:45 am – 1:45 pm and 5:15 pm – 6:45 pm, Level 1, West Hall]
• "Activity of fractionated radioimmunotherapy (RAIT) with 90Y clivatuzumab tetraxetan (90Y-hPAM4) plus gemcitabine (Gem) in advanced pancreatic cancer (APC): Final results from a two-part study." [Abstract #: 227, General Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract. Poster Board #: B35. Friday, January 20, 11:45 am – 1:45 pm and 5:15 pm – 6:45 pm, Level 1, West Hall]

About Immunomedics

Immunomedics is a New Jersey-based biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. We have developed a number of advanced proprietary technologies that allow us to create humanized antibodies that can be used either alone in unlabeled or "naked" form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins, in each case to create highly targeted agents. Using these technologies, we have built a pipeline of therapeutic product candidates that utilize several different mechanisms of action. We also have a majority ownership in IBC Pharmaceuticals, Inc., which is developing a novel Dock-and-Lock (DNL) methodology with us for making fusion proteins and multifunctional antibodies, and a new method of delivering imaging and therapeutic agents selectively to disease, especially different solid cancers (colorectal, lung, pancreas, etc.), by proprietary, antibody-based, pretargeting methods. We believe that our portfolio of intellectual property, which includes approximately 189 patents issued in the United States and more than 400 foreign patents, protects our product candidates and technologies. For additional information on us, please visit our website at www.immunomedics.com. The information on our website does not, however, form a part of this press release.

This release, in addition to historical information, may contain forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Such statements, including statements regarding clinical trials, out-licensing arrangements (including the timing and amount of contingent payments), forecasts of future operating results, potential collaborations, and capital raising activities, involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein. Factors that could cause such differences include, but are not limited to, risks associated with any cash payment that the Company might receive in connection with a sublicense involving a third party and UCB, which is not within the Company's control, new product development (including clinical trials outcome and regulatory requirements/actions), our dependence on our licensing partners for the further development of epratuzumab for autoimmune indications and veltuzumab for non-cancer indications, competitive risks to marketed products and availability of required financing and other sources of funds on acceptable terms, if at all, as well as the risks discussed in the Company's filings with the Securities and Exchange Commission. The Company is not under any obligation, and the Company expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise.